Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Colorectal Cancer

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.
Read More >>

The Rising Incidence of Early-Onset CRC: What Do We Know and What Can We Do?

West Coast Study Rates Cancer Centers by Cost and Quality

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

Grothey Grapples With Treatment Options in mCRC

Trifluridine/Tipiracil Plus Bevacizumab Improves Survival in Patients With mCRC

View More Stories >>

View Conference Coverage

2018 International Lung Cancer Congress

2018 Pan Pacific Lymphoma Conference

2nd Annual Live Medical Crossfire® : Hematologic Malignancies

State of the Science Summit on A Summer of Progress: Updates from ASCO 2018

2018 State of the Science Summit on Breast Cancer

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

Dr. Bekaii-Saab Reflects on the Findings of the ReDOS Trial in mCRC

Dr. Choti on the Role of Surgery in Rectal Cancer

Dr. Ulahannan on the VALENTINO Trial in Advanced CRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Recent Clinical Trial Data in Locally Advanced CRC

Tumor Assessment and Individualized Treatment for CRC

Standard of Care for Locally Advanced CRC

Emerging Immunotherapy Combinations in MSS CRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Biomarkers and Novel Approaches in CRC

Reverce Study: Outcomes and Impact

$Sequencing of Therapy in Refractory mCRC$

Sequencing of Therapy in Refractory mCRC

Proactive Side Effect Management With Regorafenib

Clinical Implications of the ReDOS Findings

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Treatment Goals in Refractory mCRC

$Treatment Goals in Refractory mCRC$
Tanios Bekaii-Saab, MD, FACP, Andrea Cercek, MD, and Zev A. Wainberg, MD, provide insight to the treatment goals for patients with refractory metastatic colorectal cancer.

View Now

Therapeutic Strategies in Metastatic Colorectal Cancer

Recent advances in the treatment of metastatic colorectal cancer (mCRC) have improved survival. However, many questions remain. Led by John L. Marshall, MD, panelists Tanios Bekaii-Saab, MD; Johanna Bendell, MD; Richard Kim, MD; and Charles S. Fuchs, MD, MPH, discuss strategies and approaches to managing mCRC, including the latest research and how it may influence clinical practice.

View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More